Drugmaker pins future on decoding successful cancer treatment

Drugmaker pins future on decoding successful cancer treatment


To continue reading up to 10 premium articles, you must register , or sign up and take advantage of this exclusive offer: Thalidomide was infamous for causing birth defects when Celgene Corp. transformed it into a blood-cancer treatment that brings in $7 billion a year. Now the company says it's finally figured out how Revlimid plays a key role in helping the body dispose of certain proteins.



from Biotech News